A Study to Investigate LYL845 in Adults With Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

January 9, 2025

Study Completion Date

January 9, 2025

Conditions
MelanomaNon-small Cell Lung CancerColorectal Cancer
Interventions
BIOLOGICAL

LYL845

LYL845 is an autologous tumor infiltrating lymphocyte (TIL) enhanced via Epi-R, a proprietary epigenetic reprogramming technology

Trial Locations (18)

15224

Allegheny General Hospital, Pittsburgh

20007

Georgetown University, Washington D.C.

27710

Duke University Medical Center, Durham

43210

Ohio State University Medical Center, Columbus

52242

University of Iowa Hospitals and Clinics, Iowa City

55905

Mayo Clinic Comprehensive Cancer Center, Rochester

75235

University of Texas Southwestern Medical Center, Dallas

84112

Huntsman Cancer Institute at University of Utah, Salt Lake City

90404

UCLA Medical Center, Santa Monica

94305

Stanford University, Stanford

95817

UC Davis Coomprehensive Cancer Center, Sacramento

97239

Oregon Health Sciences University, Portland

98109

Fred Hutchinson Cancer Center, Seattle

06511

Yale Cancer Center, Yale University, New Haven

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

07601

Hackensack Meridian Health Inc, Hackensack

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors
All Listed Sponsors
lead

Lyell Immunopharma, Inc.

INDUSTRY